title: Hepatitis C antibody prevalence in blood donors in different governorates in Egypt.
abstract: Markers of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections were sought in serum samples from 2644 blood donors in 24 of Egypt's 26 governorates. Of the 2644 samples, 656 (24.8%) were shown to contain anti-HCV immunoglobulin G antibody by Abbott second generation enzyme immunoassays (EIA). Of 85 EIA-positive samples tested by recombinant immunoblot assay, 72 (85%) were positive. HCV seroprevalence in the governorates ranged from zero to 38%; 15 governorates (62%) had an HCV antibody prevalence greater than 20%, and 6 (25%) greater than 30%. Governorates with higher sero-prevalences were located in the central and north-eastern Nile river delta, and south of Cairo in the Nile river valley. Subjects from areas in and adjoining the Sinai peninsula, in the eastern and western desert, and in southernmost Egypt, had the lowest prevalence of HCV antibody. The large urban governorates of Cairo and Alexandria had antibody prevalences of 19% and 11%, respectively. A total of 39.4% subjects had evidence of HBV infection (and-HBV core antigen total antibody). HCV infections were detected more frequently in donors with markers for HBV infections than in uninfected subjects (36% versus 18%, P < 0.001).
authors.affiliation: Virology Branch, United States Naval Medical Research Unit no. 3, Cairo, Egypt.
authors.forename: R R
authors.initials: RR
authors.lastname: Arthur
authors.forename: N F
authors.initials: NF
authors.lastname: Hassan
authors.forename: M Y
authors.initials: MY
authors.lastname: Abdallah
authors.forename: M S
authors.initials: MS
authors.lastname: el-Sharkawy
authors.forename: M D
authors.initials: MD
authors.lastname: Saad
authors.forename: B G
authors.initials: BG
authors.lastname: Hackbart
authors.forename: I Z
authors.initials: IZ
authors.lastname: Imam
mesh_terms: D001782:Blood Donors; D004534:Egypt / Q000453:epidemiology; D006510:Hepatitis B Antibodies / Q000032:analysis; D006526:Hepatitis C / Q000453:epidemiology* / Q000276:immunology; D018937:Hepatitis C Antibodies / Q000032:analysis*; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D015995:Prevalence
chemical_list: D006510:Hepatitis B Antibodies; D018937:Hepatitis C Antibodies; D007074:Immunoglobulin G